Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 3/20 | 0.64 |
| ▸ | TK1 | P04183 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.60 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.60 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.60 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.60 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | TK2 | O00142 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deoxyuridine SCHEMBL9219261 | 1.00 | DUT (0.64) | DUTTK1LMNASMN1; SMN2SLC28A1 | |
| Deoxyuridine SCHEMBL889540 | 1.00 | DUT (0.64) | DUTTK1LMNASMN1; SMN2SLC28A1 | |
| Deoxyuridine SCHEMBL114598 | 1.00 | DUT (0.64) | DUTTK1LMNASMN1; SMN2SLC28A1 | |
| Deoxyuridine SCHEMBL19841232 | 1.00 | DUT (0.64) | DUTTK1LMNASMN1; SMN2SLC28A1 | |
| Deoxyuridine SCHEMBL9708874 | 1.00 | DUT (0.64) | DUTTK1LMNASMN1; SMN2SLC28A1 | |
| Deoxyuridine SCHEMBL24512520 | 1.00 | DUT (0.64) | DUTTK1LMNASMN1; SMN2SLC28A1 | |
| Deoxyuridine SCHEMBL4847464 | 1.00 | DUT (0.64) | DUTTK1LMNASMN1; SMN2SLC28A1 | |
| Deoxyuridine SCHEMBL391224 | 1.00 | DUT (0.64) | DUTTK1LMNASMN1; SMN2SLC28A1 | |
| Deoxyuridine SCHEMBL9219265 | 1.00 | DUT (0.64) | DUTTK1LMNASMN1; SMN2SLC28A1 | |
| Deoxyuridine SCHEMBL28844 | 1.00 | DUT (0.64) | DUTTK1LMNASMN1; SMN2SLC28A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20250381110-A1 | SKIN CARE COMPOSITION AND METHOD OF USING THE SAME | PROCTER & GAMBLE (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4543898-A1 | PYRIMIDINE NUCLEOSIDE TREATMENTS | The Children's Medical Center Corporation (US) | 2025-04-30 | — | — | EP | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2024020221-A1 | MODULATORS OF TYK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| WO-2023250015-A1 | PYRIMIDINE NUCLEOSIDE TREATMENTS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-12-28 | — | — | WO | disclosed |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-7517646-B2 | Functional molecule and process for producing the same | FUJITSU LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20080214404-A1 | Functional molecule binding specifically to membrane protein, and manufacturing method therefor | FUJITSU LIMITED (JP) | 2008-09-04 | — | — | US | disclosed |
| US-20080214404-A1 | Functional molecule binding specifically to membrane protein, and manufacturing method therefor | FUJITSU LIMITED (JP) | 2008-09-04 | — | — | US | disclosed |
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | SEGEV LABORATORIES LIMITED (IL) | 2008-01-03 | — | — | US | disclosed |
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | SEGEV LABORATORIES LIMITED (IL) | 2008-01-03 | — | — | US | disclosed |
| US-20070232793-A1 | Functional molecule and manufacturing method therefor | FUJITSU LIMITED (JP) | 2007-10-04 | — | — | US | disclosed |
| US-20070232793-A1 | Functional molecule and manufacturing method therefor | FUJITSU LIMITED (JP) | 2007-10-04 | — | — | US | disclosed |
| US-20070231855-A1 | Functional molecule and manufacturing method therefor | FUJITSU LIMITED (JP) | 2007-10-04 | — | — | US | disclosed |
| US-20070231855-A1 | Functional molecule and manufacturing method therefor | FUJITSU LIMITED (JP) | 2007-10-04 | — | — | US | disclosed |
| US-20070190546-A1 | Methods and compositions for sequencing a nucleic acid | FLUIDIGM CORPORATION | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | DUT 3691/4885TK1 1825/4885LMNA 2024/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | DUT 3897/4885TK1 372/4885LMNA 2696/4885 |
| US-20070232793-A1 | Functional molecule and manufacturing method therefor | TNFSF11, VSIG8, ADAM8 | DUT 2142/4885TK1 3668/4885LMNA 3016/4885 |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | UCHL1, ADRM1, CRBN | DUT 3328/4885TK1 2497/4885LMNA 1946/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | DUT 1409/4885TK1 2622/4885LMNA 287/4885 |
| US-20070190546-A1 | Methods and compositions for sequencing a nucleic acid | RNGTT, POLN, NT5C3B | DUT 54/4885TK1 189/4885LMNA 537/4885 |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | LRRK2, ADRM1, CRBN | DUT 4113/4885TK1 2291/4885LMNA 2534/4885 |
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | RCC1, NUMA1, ACIN1 | DUT 269/4885TK1 17/4885LMNA 107/4885 |
| US-20250381110-A1 | SKIN CARE COMPOSITION AND METHOD OF USING THE SAME | SQSTM1, BECN1, CUTA | DUT 4183/4885TK1 2352/4885LMNA 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.